50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Gold is about to SOAR – here’s what you need to do (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Gold is about to SOAR – here’s what you need to do (Ad)
Closing prices for crude oil, gold and other commodities
Dow sinks to 2022 low as recession fears roil world markets
CEO of biggest PE firm predicts “social unrest” (Ad)
'Crucial' vote could move Italy to right; many might boycott
MarketBeat: Week in Review 9/19 – 9/23
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Gold is about to SOAR – here’s what you need to do (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Gold is about to SOAR – here’s what you need to do (Ad)
Closing prices for crude oil, gold and other commodities
Dow sinks to 2022 low as recession fears roil world markets
CEO of biggest PE firm predicts “social unrest” (Ad)
'Crucial' vote could move Italy to right; many might boycott
MarketBeat: Week in Review 9/19 – 9/23
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Gold is about to SOAR – here’s what you need to do (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Gold is about to SOAR – here’s what you need to do (Ad)
Closing prices for crude oil, gold and other commodities
Dow sinks to 2022 low as recession fears roil world markets
CEO of biggest PE firm predicts “social unrest” (Ad)
'Crucial' vote could move Italy to right; many might boycott
MarketBeat: Week in Review 9/19 – 9/23
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Gold is about to SOAR – here’s what you need to do (Ad)
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Gold is about to SOAR – here’s what you need to do (Ad)
Closing prices for crude oil, gold and other commodities
Dow sinks to 2022 low as recession fears roil world markets
CEO of biggest PE firm predicts “social unrest” (Ad)
'Crucial' vote could move Italy to right; many might boycott
MarketBeat: Week in Review 9/19 – 9/23

Marinus Pharmaceuticals - MRNS Stock Forecast, Price & News

$7.06
+0.25 (+3.67%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.24
$7.07
50-Day Range
$5.17
$7.51
52-Week Range
$3.97
$13.15
Volume
492,030 shs
Average Volume
183,357 shs
Market Capitalization
$262.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.17

Marinus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
355.6% Upside
$32.17 Price Target
Short Interest
Healthy
3.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
1.64mentions of Marinus Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.90) to ($3.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

306th out of 1,080 stocks

Pharmaceutical Preparations Industry

126th out of 535 stocks

MRNS stock logo

About Marinus Pharmaceuticals (NASDAQ:MRNS) Stock

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRNS Stock News Headlines

Marinus Pharmaceuticals: Positive News Flow Of Note
Revisiting Marinus Pharmaceuticals
See More Headlines
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRNS Company Calendar

Last Earnings
8/11/2022
Today
9/24/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNS
Employees
113
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.17
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+355.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-98,780,000.00
Net Margins
-386.11%
Pretax Margin
-386.11%

Debt

Sales & Book Value

Annual Sales
$15.35 million
Book Value
$1.34 per share

Miscellaneous

Free Float
35,681,000
Market Cap
$262.63 million
Optionable
Optionable
Beta
1.36

Key Executives

  • Dr. Scott N. Braunstein M.D. (Age 59)
    CEO, Pres & Director
    Comp: $869.03k
  • Mr. Steven E. Pfanstiel C.M.A. (Age 49)
    M.B.A., CFO & Treasurer
    Comp: $553.91k
  • Dr. Joseph Hulihan M.D. (Age 66)
    Chief Medical Officer
    Comp: $621.91k
  • Ms. Sasha Damouni Ellis
    VP of Corp. Affairs & Investor Relations
  • Ms. Martha E. Manning (Age 67)
    VP, Gen. Counsel & Sec.
  • Mr. Thomas J. Lyons
    Sr. VP of Corp., Bus. Devel. & Commercial Planning
  • Ms. Lisa Lejuwaan
    VP of Sales
  • Ms. Sonya Weigle
    VP of HR
  • Dr. Kimberly A. McCormick Pharm.D.
    PharmD, Sr. VP and Head of Regulatory Affairs & Quality Assurance
  • Dr. Alex Aimetti Ph.D.
    Sr. VP of Scientific Affairs













MRNS Stock - Frequently Asked Questions

Should I buy or sell Marinus Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRNS shares.
View MRNS analyst ratings
or view top-rated stocks.

What is Marinus Pharmaceuticals' stock price forecast for 2022?

5 brokerages have issued 12 month price objectives for Marinus Pharmaceuticals' stock. Their MRNS share price forecasts range from $22.00 to $50.00. On average, they predict the company's share price to reach $32.17 in the next year. This suggests a possible upside of 355.6% from the stock's current price.
View analysts price targets for MRNS
or view top-rated stocks among Wall Street analysts.

How have MRNS shares performed in 2022?

Marinus Pharmaceuticals' stock was trading at $11.88 at the start of the year. Since then, MRNS shares have decreased by 40.6% and is now trading at $7.06.
View the best growth stocks for 2022 here
.

When is Marinus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our MRNS earnings forecast
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its earnings results on Thursday, August, 11th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by $0.13. The biopharmaceutical company had revenue of $1.79 million for the quarter, compared to analysts' expectations of $2.25 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 266.12% and a negative net margin of 386.11%.

When did Marinus Pharmaceuticals' stock split?

Shares of Marinus Pharmaceuticals reverse split on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Marinus Pharmaceuticals own?
What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (1.18%), Millennium Management LLC (1.03%), FMR LLC (0.68%), Renaissance Technologies LLC (0.42%), State Street Corp (0.35%) and Assenagon Asset Management S.A. (0.29%). Insiders that own company stock include Edward F Smith and Scott Braunstein.
View institutional ownership trends
.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $7.06.

How much money does Marinus Pharmaceuticals make?

Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $262.63 million and generates $15.35 million in revenue each year. The biopharmaceutical company earns $-98,780,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis.

How many employees does Marinus Pharmaceuticals have?

The company employs 113 workers across the globe.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for the company is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at lcaperelli@marinuspharma.com, or via fax at 203-315-0565.

This page (NASDAQ:MRNS) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.